SCHEDULE: Parag Saxena Cuts Reviva Pharma Stake to 2.8%

Parag Saxena has reduced his beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. to 2.8% as of March 20, 2026, triggering an Amendment No. 13 filing.

Summary

• Parag Saxena, the Reporting Person, filed Amendment No. 13 to Schedule 13D, amending and supplementing previous filings.
• Beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. (Issuer) decreased to an aggregate of 363,280 shares.
• This represents approximately 2.8% of the Issuer's outstanding common stock.
• The percentage is based on 12,810,377 outstanding shares of common stock as of March 20, 2026.
• Mr. Saxena ceased to be a beneficial holder of more than five percent of the Issuer's Common Stock on March 20, 2026.
• Holdings include 45,047 shares held directly, 46,550 shares by Vedanta Associates-R, 19,950 shares by Beta Operators, 4,977 shares by Vedanta Associates, and shares underlying various warrants and vested options.
• No transactions were effected by the Reporting Person in any securities of the Issuer during the past sixty (60) days from the filing date.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative development, as the reduction of a significant investor's stake below 5% often signals diminished confidence or a strategic shift, which can weigh on market sentiment.

Negatives

• A significant investor, Parag Saxena, has reduced his beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. below the 5% threshold.
• This reduction could signal a decrease in investor confidence or a strategic divestment by a long-term holder.

Risks

• The reduction in beneficial ownership by a significant investor may negatively impact market sentiment towards Reviva Pharmaceuticals Holdings, Inc.
• A decrease in institutional ownership could lead to reduced liquidity or increased volatility in the stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a reduction in a significant investor's stake, especially below the 5% threshold, can be a notable event in the biotechnology and pharmaceutical sectors. Such moves are often scrutinized by the market for potential signals regarding the company's future prospects or the investor's portfolio strategy, though this filing does not provide the rationale for the reduction.

Related Party Transactions

• Parag Saxena's beneficial ownership includes shares held by entities such as Vedanta Associates-R, Beta Operators, and Vedanta R2, indicating related party holdings under his control.

Stakeholder Impact

• Shareholders: May interpret the reduction in stake by a significant investor as a negative signal, potentially leading to downward pressure on the stock price.
• Company Management: Could face questions regarding investor confidence and strategic direction following the divestment by a major holder.

Key Dates

Recommendation

A seasoned investor would likely view the reduction of a significant, long-term investor's stake below the 5% threshold as a strong negative signal. This often suggests a loss of conviction in the company's future prospects or a strategic divestment, which could precede further selling pressure or a decline in market sentiment. Without any offsetting positive news, reducing exposure or selling the stock would be a prudent move.

Keywords

Reviva Pharmaceuticals, Parag Saxena, Schedule 13D, Beneficial Ownership, Stake Reduction, Common Stock, Vedanta Management, Biotechnology, Pharmaceuticals